Anno 1997

swipe-left
 TitoloAutoriRivista
1Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Gebbia V, Borsellino N, Testa A, Latteri MA, Milia V, Valdesi M, Giotta F, Gebbia N, Colucci G.Anticancer Drugs. 1997 Nov;8(10):943-8. doi: 10.1097/00001813-199711000-00005. PMID: 9436637.
2Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). Colucci G, Gebbia V, Galetta D, Riccardi F, Cariello S, Gebbia N.Br J Cancer. 1997;76(11):1509-17. doi: 10.1038/bjc.1997.586. PMID: 9400950; PMCID: PMC2228170.
3Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group. Colucci G, Giotta F, Gebbia V, Riccardi F, Pezzella G, Durini E, Caruso M, Romito S, Gebbia N.Anticancer Drugs. 1997 Mar;8(3):257-64. doi: 10.1097/00001813-199703000-00006. PMID: 9095330.

L'area riservata ai soci GOIM sarà presto disponibile